A Mom and Tech Entrepreneur Building AI Advocate for Rare-Disease Families Like Hers

Why It Matters

The tool democratizes specialist advocacy for rare‑disease patients, improving daily care and shortening the path to FDA‑approved therapies, which could translate into billions of dollars saved and better outcomes across a fragmented market.

Key Takeaways

• Citizen Health raised $44M to build AI advocate for rare‑disease families.
• Platform serves 8,000 patients across 350+ rare diseases, free for users.
• AI schedules appointments, navigates insurance appeals, and connects patients to trials.
• 98.3% of users opt‑in to share data, speeding research.
• FDA accepted patient data, letting foundation skip $80M phase‑three trial.

Pulse Analysis

Artificial intelligence is reshaping healthcare, but rare‑disease patients have lagged behind because data are scarce and expertise is dispersed. Citizen Health leverages large‑language models combined with a curated, consent‑driven data pool to create an "AI advocate" that can perform administrative tasks and surface relevant clinical information. By automating routine burdens—scheduling, insurance navigation, trial matching—the platform frees caregivers from the average 53 hours per week they currently devote to care, allowing them to focus on treatment decisions and quality of life.

The company’s data strategy is equally transformative. With more than 8,000 participants covering 350+ conditions, the network supplies pharmaceutical partners with real‑world evidence that shortens development cycles by up to half. Researchers can query anonymized genetic and phenotypic records, accelerating hypothesis generation and patient‑centric endpoint selection. This collaborative model not only improves trial enrollment efficiency but also creates a revenue stream that shares a portion of commercial licensing fees back with the contributing patients, reinforcing a virtuous data‑sharing loop.

Investor interest reflects the broader market shift toward patient‑empowered health tech. Backers such as 8VC, Headline, and the Chan Zuckerberg Initiative see Citizen Health as a template for scaling AI‑driven advocacy across other underserved disease spaces. As regulatory bodies like the FDA increasingly accept patient‑generated data for trial design, platforms that combine AI assistance with robust, consent‑based datasets are poised to become essential infrastructure in the next wave of precision medicine.